That approval was based on a phase 3 study that demonstrated a 46% reduction in the risk of disease progression or death, and a 27% reduction in the risk of death compared with Tecentriq alone. In ...

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed.

CHICAGO—At the world’s largest oncology conference, Ozempic, a diabetes drug, found its way to the center of the conversation. As thousands of attendees bounced between presentations at the American ...

Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the odds of a tumor developing. By Nina Agrawal Scientists have made a discovery ...

As we age, our cells acquire cancer-causing mutations, but mutations alone are rarely enough to start a tumor. An environmental trigger, such as exposure to air pollution from sources such as ...

Eli Lilly and Co.’s cancer drug Retevmo has shown promise in helping patients combat a form of early-stage lung cancer, according to results from a late-stage clinical trial. The Indianapolis-based ...

An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of ...

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. And the first-in-class PD-1xVEGF bispecific didn’t disappoint—at least on its ...

Matthew Herper covers medical innovation — both its promise and its perils. CHICAGO — Ivonescimab, a drug that combines the activity of two of the best-selling cancer medicines, reduced the risk of ...

Chinese biopharma company Kelun-Biotech announced on Thursday that an antibody drug conjugate it is developing with Merck (MRK), with Keytruda, outperformed the U.S. drugmaker’s anti-PD-1 therapy in a ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...